Trials / Completed
CompletedNCT05406180
Postmarketing Surveillance Study for Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) in Subjects Aged 3 Years Old and Above
Postmarketing Surveillance Study for Use of Quadrivalent Influenza Vaccine (VaxigripTetra Inj.) Administered Via the Intramuscular Route in Subjects Aged 3 Years Old and Above in the Republic of Korea
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 675 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 3 Years
- Healthy volunteers
- Accepted
Summary
The objective is to describe the safety profile after 1 dose of VaxigripTetra inj. administered in subjects aged 3 years old and above under routine clinical practice. The planned duration of each subject's participation in the study will be 21 to 28 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | VaxigripTetra inj. | Suspension for injection in a pre-filled syringe Injection intramuscular |
Timeline
- Start date
- 2018-10-10
- Primary completion
- 2019-12-27
- Completion
- 2019-12-27
- First posted
- 2022-06-06
- Last updated
- 2022-06-06
Locations
10 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05406180. Inclusion in this directory is not an endorsement.